JP4487277B2 - Foods and beverages and pharmaceuticals such as health foods - Google Patents

Foods and beverages and pharmaceuticals such as health foods Download PDF

Info

Publication number
JP4487277B2
JP4487277B2 JP2001298490A JP2001298490A JP4487277B2 JP 4487277 B2 JP4487277 B2 JP 4487277B2 JP 2001298490 A JP2001298490 A JP 2001298490A JP 2001298490 A JP2001298490 A JP 2001298490A JP 4487277 B2 JP4487277 B2 JP 4487277B2
Authority
JP
Japan
Prior art keywords
collagen
foods
type
present
health
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001298490A
Other languages
Japanese (ja)
Other versions
JP2002173446A (en
Inventor
誠二 坪井
司甫 横山
Original Assignee
司甫 横山
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 司甫 横山 filed Critical 司甫 横山
Priority to JP2001298490A priority Critical patent/JP4487277B2/en
Publication of JP2002173446A publication Critical patent/JP2002173446A/en
Application granted granted Critical
Publication of JP4487277B2 publication Critical patent/JP4487277B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【0001】
【産業上の利用分野】
本発明は特定のコラーゲン(これを含む生体成分)より成る健康食品等の飲食物及び医薬品に関する。更に本発明はタイプIVコラーゲンより及び又はその分画やペプタイドより成るもしくはこれらを認識する抗体より成る抗癌剤に関する。更に骨由来コラーゲン(これを含む生体成分)及び又はタイプIコラーゲン及び又はタイプIIIコラーゲン(これらを含む生体成分)より成る骨粗鬆症予防及び改善治療剤又は健康食品等の飲食物に関する。
【0002】
【従来の技術】
「医食同源」とは病気を治すこと(薬物療法)も食事をするのも命を養い健康を保つためで、その本質は同じであるということである。この考えに立てば、日常摂取している飲食物には病気予防や治療の本質物質が存在する事になる。それ故、日常飲食している物から、有効成分を見出だして濃縮や精製し、日常的に疾患を予防し抑制することが健康食品や医薬品として望ましいと発明者は考える。飲食物として摂取する時には、人体成分に近い構成物のものが望ましく、例えば動物成分が、特に望ましいと考える。
しかし実際には、関節疾患患者に、関節成分のコンドロイチン硫酸やタイプIIコラーゲン(特に断らない限りコラーゲンとゼラチンは同義に用いる)を直接摂取するか又はこれらを主に含む生体成分や抽出スープとして摂取しているのみであり、治療改善に有効量が摂取されているか不明である。
又、従来の癌治療、特に固形癌の治療は、化学療法やホルモン療法などの全身的な方法と、手術や放射線療法などの局所療法が行われている。しかし、癌は治らないという諦観から、いずれも延命などの緩やかな治療を目指すようにようになっている。実際、転移し易い癌、例えば肝細胞癌は、脈管内に浸潤する傾向が強く、特に門脈へ浸潤する傾向が強く、治療に苦慮している。この場合、局所的な治療(肝臓動脈塞栓術、経皮的エタノール注入療法・マイクロ波凝固療法・ラジオ波焼灼療法)では、対処困難である。又、化学療法は、いずれの薬剤の単独投与でも有効率が10%程度と低く、副作用も強く、有効な治療方法とは言えない。
【0003】
【発明が解決しょうとする問題点】
本発明の目的は前記「医食同源」の考えに応え、食品中より、動物由来の有効物質、特に特定のコラーゲンを用いて健康食品等の飲食物及び医薬品として提供することにある。
更に本発明の目的は、新しいバイオ利用の抗癌剤で特に増殖性や転移性の強い癌を抑制する抗癌剤の開発にある。
又、近年多く見られる骨粗鬆症では、骨由来物や生体由来の有効物質の投与が望まれるが、実際の治療や予防には、カルシュウムや骨粉が適用されそれ以外ではビタミンK、D群が適用されているにすぎず、めぼしい生体由来の有効成分がない。この現状を打破すべく発明者は鋭意研究し、特定のコラーゲンを特定量用いて解決することを見出だした。
一方、癌細胞は活動が活発になると基底膜を破壊して拡大するが、有効な生体由来の薬剤はなかった。又、従来、癌疾患の治療剤は、長期投与では副作用が強いという欠点があった。長期の治療で副作用がなく安心して投与できる癌疾患の治療薬が望まれていた。本発明は有効物質として基底膜の主成分であるタイプIVコラーゲン及びその抗体を利用して、癌の転移と増殖を抑制することにある。
【0004】
【発明の構成】
本発明は、生体各部の中心的成分の特定のコラーゲンを抽出し、これを健康食品等の飲食物及び医薬品とすることに関する。更に、本発明はタイプIVコラーゲン及び又はその分画やペプタイド自身より成る加えてこれらを認識する抗体より成る抗癌剤に関する。
抗癌剤とするコラーゲンの種類は、各タイプの混合でも単独でも良いが単独では特にタイプIVコラーゲンが望ましい。抗癌剤とするコラーゲンの用いる部分はコラーゲン全体でも良く、又その部分を構成する分画やペプタイドでも良く、又、これらの混合物でも良い。通常、タイプIVコラーゲンは、NC1(C末端非螺旋部)、中央三本鎖螺旋部(内部に乱れ有り)、7S(N末端三本鎖螺旋部)の三領域に分けられ、更に、それぞれが、アルファ1から6まで分画されるが、抗癌剤とする時これらを単独又は組み合わせて使用して良く、望ましくは三本鎖螺旋部(中央及び又はN末端、以下三本鎖)を、更に望ましくは三本鎖のアルファ1及び又はアルファ2であり、そのペプタイドである。タイプIVコラーゲンの三本鎖は、由来臓器(胎盤、腎糸球体、眼レンズカプセル、各種組織基底膜)、抽出条件及び精製条件で得られる分子量は異なるが、いずれでも良く、特に望ましくは、電気泳動した時、約180Kから約160Kに属するものや約30Kよりも、約50Kから約100Kに属するものである。
【0005】
コラーゲンは生体内に存在し、各種の型があり、安全な成分である。コラーゲンは、体蛋白の約30%を占めるので、健常者は、日常の食事で動物蛋白源としてコラーゲンを常時取り込んでいる。例えば、動物を生食(例えば生卵、ステーキレア、馬刺、魚類の刺身、鮭頭軟骨の酢の物)し、又動物を加熱調理し、干物を食べ、抽出(例えば軟骨を含むスープ類)して食することで生体内に取り込んでいる。コラーゲンは、菓子類(通称グミ)や健康食品としても広く利用され、安全に経口摂取できる。又、コラーゲンは、動物細胞の培養時に、足場として安全に細胞を増殖するのに用いられている。更に、変性コラーゲン(ゼラチン)が、ワクチン、内服薬や注射薬に、賦形剤、安定剤等として添加されている。
【0006】
本発明者は、長年の研究の結果、正常で組織特有なコラーゲンを含む結合組織の強化は、その組織の疾患の進展を抑制することを見出だした。更にその強化の為には、正常で組織特有なコラーゲンの投与が良いとすることを見出だした。
【0007】
コラーゲンは、手に入りやすい組織のもの、例えば、真皮由来のタイプI、IIIコラーゲンや、胎盤由来のタイプIVコラーゲンでも良いが、治療対象組織に含まれる型のコラーゲンと同一型が好ましく、最も好ましいのは改善や治療対象もしくは強化対象の組織由来のものであるがこれに限定されない。
【0008】
コラーゲンは通常テロペプチドを含んでいるもの及びこれを除去したものが知られており、本発明においては両者のものを単独、もしくは混合して使用可能であるが、抗原性の面からテロペプチドを除去したものの方が好ましい。更に本発明に於いてコラーゲンは、変性、修飾、低分子化したものでも、ペプタイド合成機で製したものでもこれらを組み合わせたものでも良い。つまり変性させてゼラチンにしても良く、サクシニル化などの修飾をしたものでも、低分子化したものでも良い。
【0009】
本発明に於いてコラーゲンの由来は哺乳類、鳥類、魚類、甲殻類、爬虫類、昆虫類、菌類等、例えば、ヒト、サル、牛、豚、鯨、ラット、マウス、馬、家兎、山羊、ニワトリ、魚、カニ、えび、カエル、蚕、昆虫、大腸菌等のいづれの生物でもよく、これらを混合して用いてもよい。
【0010】
コラーゲンの製法は、生体抽出、組織・細胞培養、遺伝子工学的製法等すでに知られている方法(「細胞外マトリックス研究法」コラーゲン技術研修会刊行)、又、ペプタイド合成機で製してのいずれでも良い。
コラーゲンを生体から製するには、一般的には塩酸や酢酸等の酸抽出とペプシン等の酵素抽出があり、両者を組合わせても良い。更にDEAEカラムクロマトグラフィーや分画分子量の透析で、微量ならHPLCで精製しても良い。
1)胎盤よりタイプIVコラーゲンを製する一例を示す。
以下、できる限り4Cで行う。ヒト胎盤を細裁断し洗浄(精製水−蛋白分解酵素阻害剤含有0.05Mトリス緩衝液pH7.5−精製水)−凍乾し粉砕−ペプシン含有0.5M酢酸(酢酸のみでも良い)で可溶化し遠心で上清を採取(沈殿は再可溶化、約5回繰り返す)−終濃度0.7M塩化ナトリウムを添加−遠心で上清を採取−終濃度1.2M塩化ナトリウム添加−遠心で沈殿採取−1M塩化ナトリウム含有0.05Mトリス緩衝液pH7.5に溶解透析−4.5M塩化ナトリウムを添加−遠心で沈殿採取−1.0M塩化ナトリウム含有0.05Mトリス緩衝液pH7.5に溶解透析−遠心で上清採取−4.5M塩化ナトリウム添加−沈殿(タイプIVコラーゲン)−カラムクロマトグラフィーで精製。
なお公開特許公報(昭和62−53927)にも製する例がある。
2)胎盤よりタイプI及びIIIコラーゲンを製する一例を示す。
以下、できる限り4Cで行う。ヒト胎盤を細裁断−洗浄(蛋白分解酵素阻害剤含有PBS)と遠心で沈殿を採取(この操作を約6回繰り返す)−凍乾し粉砕−ペプシン含有0.5M酢酸(酢酸のみでも良い)で可溶化し遠心で上清を採取(沈殿は再可溶化、約5回繰り返す)−終濃度2M塩化ナトリウムを添加−遠心で沈殿を採取−0.05M酢酸に溶解−遠心で上清採取−終濃度1M塩化ナトリウムを添加−遠心で沈殿を採取−0.05M酢酸に溶解−透析し遠心分離−上清(タイプI)、沈殿(タイプIII)−更に透析し精製。
なお、真皮よりタイプI及びIIIコラーゲンを製する時、例えば、ウシ胎児、子ウシの真皮を用いる時は、皮膚の除毛、脂肪の除去を充分に行う。脱脂には、ジエチルエーテルとエタノールの混合液(1:1)を用いる。
【0011】
更に抗癌剤として使用する場合は、本発明に於けるコラーゲンのみでなく、これに対する抗体を用いることも可能である。抗体を用いる場合は、ポリクローナルよりもモノクローナルが望ましく、より望ましくは、ヒト型モノクローナル抗体である。
マウスやラットのモノクローナル抗体をヒトに投与した時、長期では中和抗体ができ効果が弱まるが、ヒト型ではこのような事が起きにくい。抗体としてのイムノグロブリンは、IgG1やG2aなどのIgGやIgM及び他の型でも,各型混合したものでも良く、更に小さくしたもの、例えばH鎖、L鎖、Fc、Fab、F(ab′)、その他などでも抗原と反応性を持つ限り良い。
【0012】
本発明として使用する健康食品等の飲食物とは、いわゆる健康食品のみならず、特定保健用食品、医薬部外品、一般飲食物等、任意の食品形態を含む。
【0013】
本発明のコラーゲンとしての1日量は通常、健康食品等の飲食物としては、0.1g以上であればよく、好ましい範囲として1g〜100g、特に好ましい範囲として5〜10gをあげることができる。
骨粗鬆症薬としての本発明のコラーゲンは、1日1〜30gが良く、好ましくは1日5〜15gが良い。
抗癌剤としての本発明のコラーゲン量は、1日0.001mg以上30g以下で、好ましくは1日0.01mg〜10gで、抗体量としては1日0.001mg以上30g以下で、好ましくは1日0.01mg〜10gである。数値は目安であり、疾患の重傷度、服用者の状態により増減されるべきで、これに限定されない。
【0014】
本発明の投与方法は、経口投与、注射、生体内留置等、通常、医療現場や食品として利用されている方法なら特に限定されない。投与時期は、食後、食間、就寝前のいずれでも、又これらを組み合わせても良く、1日の投与回数も特に限定しない。
例えば、抗癌剤としてタイプIVコラーゲンを用い、転移性肝癌に局所的な治療を行う時である。タイプIVコラーゲン0.01mg〜1gを単独又はこれを含む微粒子を肝臓動脈へカテーテルから注入し血管造影で確認しながら塞栓を形成させることで、抗癌剤の転移と増殖を抑制する。
【0015】
本発明の摂取(投与)形態は、末、錠、液、カプセル等既存の健康食品や医薬品の形態で良い。内服の形態の時の賦形剤には、内服の形態に必要とし通常用いられるものが適応できる。例えば、増量剤としては澱粉、乳糖などである。必要に応じ、香味料、甘味料、着色料、賦形剤などを添加しても良い。
【0016】
更に既存医薬品の様に注射剤にしても、内服剤にしても、外用剤としても、局所投与形態にしても良い。
又主剤はコラーゲン単独や抗体単独でも、他の薬物と混合して内服薬、注射剤にしても良い。他の薬物は特に限定されず、通常医薬品として使用可能な薬物、例えば消化剤、整腸剤、抗潰瘍剤、抗生物質、ホルモン、酵素、ステロイド、内分泌系用薬、循環器系剤、抗リウマチ剤、抗炎症剤、鎮痛剤、解熱剤、抗アレルギー剤、抗腫瘍剤、更にはインターフェロン、インターロイキン、腫瘍壊死因子等のペプチド等をあげることができる。
【0017】
本発明の健康食品等の飲食物や内服薬、注射剤等の医薬品に於いて溶液として用いる時、溶液は、滅菌精製水、水溶性溶剤(例えば、グリセリン)、油性溶剤(例えば、精製オリーブ油)等を単独又は組み合わせて使用することができる。又、本発明の健康食品等の飲食物や内服薬、注射剤等の医薬品に於いては、添加剤として等張化剤、緩衝剤、溶解補助剤、界面活性剤、安定化剤、防腐剤、油脂類、水溶性高分子、局所麻酔剤等を添加してもよい。その等張化剤としては塩化ナトリウム等の無機塩を、緩衝剤としてはリン酸等の無機酸、及びクエン酸の有機酸を、界面活性剤としてはゼラチン、ポリソルベート80、油脂類としては植物油等を、水溶性高分子としてはカルボキシメチルセルロースナトリウム等をあげることができる。
更に、本発明の健康食品等の飲食物、内服溶液剤、注射剤において、このように製された溶液、もしくは懸濁液に等張化剤、緩衝剤以外の前記添加物を、溶解もしくは懸濁させてもよい。
このように製された溶液、もしくは懸濁液をミリポアフィルター等を用いて無菌化し、次いで瓶、バイアルもしくは、アンプルに充てんさせることにより本発明の健康食品液、内服液、注射剤を製することができる。又本発明の液においては製された瓶、バイアルもしくはアンプルを凍結乾燥し、用時溶解液とすることも可能である。
【0018】
【発明の効果】
医食同源の発想から、日常の飲食物から、特に動物成分から、必要な有効成分を得て、これを健康食品あるいは医薬品の形態とし、生体内で効率良く摂取可能とし、疾病の予防及び治療に提供するものである。又、その抗体についても同様である。特にコラーゲンは2か月以上の長期に渡って使用しても自他覚の副作用を認めない安全な健康食品等の飲食物及び薬剤である。
以下、本発明を更に実施例で説明するが本発明はこれらにより限定されるものではない。
【0019】
【実施例1−1】
基底膜の主要成分であるタイプIVコラーゲンのNC1(ウシ由来、ここでは腎臓由来を使用)、タイプIVコラーゲン(ヒト由来、ここでは胎盤由来でペプシン処理を使用、以下3本鎖)及び抗体(ウサギ由来、ここでは抗NC1抗血清)の抗癌作用につき検討した。
癌細胞(HEPG2)の培養液にNC1、3本鎖及びその抗血清を加えて比較した。
結果は、3本鎖が最も癌細胞の増殖を抑制した。抗血清(ウサギ由来)も抑制効果があった。NC1(ウシ由来)も濃度を上げると抑制した。

Figure 0004487277
*各6穴の平均細胞数
*培養条件 BMEM+10%FBS、5%CO濃度、37C
【0020】
【実施例1−2】
細胞「B16 マウスメラノーマ(黒色腫)」を用い、「実施例1−1」に準じて培養実験をした。Type I collagen(ヒト胎盤由来、以下の実験も同様)。
Figure 0004487277
【0021】
【実施例1−3】
細胞「FBJLL マウスOsteocarcunoma」を用い、「実施例1−1」に準じて培養実験をした。
Figure 0004487277
【0022】
【実施例1−4】
細胞「OVCAR4 ヒトOvarian cancer cell」を用い、「実施例1−1」に準じて培養実験をした。
Figure 0004487277
【0023】
【実施例1−5】
細胞「HT1080 ヒトFibrosarcoma」を用い、「実施例1−1」に準じて培養実験をした。
Figure 0004487277
【0024】
【実施例1−6】
細胞「ヒトHuman gastric carcinoma」を用い、「実施例1−1」に準じて培養実験をした。
Figure 0004487277
【0025】
【実施例2】
安全性
コラーゲンの健常者への影響について確認した。健常者ボランテア2名が、豚骨由来コラーゲン(タイプIコラーゲン80%以上 コラーゲン技術研修会)約10%を含有する市販スポーツドリンク(大塚製薬)液を暖め、1日2回食後に約100ml(コラーゲン含量約10g)を1か月服用したが、使用中、使用直後も更に服薬休止1か月後も特段の自覚変化は見られなかった。
【0026】
【実施例3】
有効性
毎日の散歩を1時間以上行う骨粗鬆症患者3名が充分な同意の上で豚骨由来コラーゲン(タイプIコラーゲン80%以上 コラーゲン技術研修会)を市販スポーツドリンク(大塚製薬)液に暖めて溶解し内服した。内服量は、1日3回食後にコラーゲン各5gに相当する。
その結果、1名は最短1か月より骨密度が3%上昇し、2ヵ月後には8%の上昇であった。他の2名は変化が見られなかった。
【0027】
【実施例4】
有効性
骨折経験のある骨粗鬆症患者(70才、女子)が事前の充分な同意の上で、豚真皮由来コラーゲン(タイプI及びタイプIIIコラーゲン コラーゲン技術研修会)を毎日1回就寝前に、約10gをオレンジジュース40ml(ビタミンC約10mg相当含有)に懸濁させて40日間内服した。その結果、骨密度が5%上昇した(DEXA法による測定誤差は2%以内)。[0001]
[Industrial application fields]
The present invention relates to foods and drinks such as health foods and pharmaceuticals comprising specific collagen (a biological component containing the same). Furthermore, the present invention relates to an anticancer agent comprising type IV collagen and / or an antibody comprising or recognizing a fraction or peptide thereof. Furthermore, the present invention relates to a food and drink such as osteoporosis prevention and amelioration therapeutic agent or health food comprising bone-derived collagen (a biological component containing this) and / or type I collagen and / or type III collagen (a biological component containing these).
[0002]
[Prior art]
“Medical food companion” means to cure the disease (pharmacotherapy) and to eat to feed and maintain health, and the essence is the same. Based on this idea, there are essential substances for disease prevention and treatment in food and drink taken daily. Therefore, the inventor believes that it is desirable for health foods and pharmaceuticals to discover and concentrate and purify active ingredients from things that are eaten and consumed daily, and to prevent and control diseases on a daily basis. When ingesting as a food or drink, it is desirable that the composition is close to the human body component, for example, an animal component is particularly desirable.
However, in practice, patients with joint diseases take joint components chondroitin sulfate and type II collagen (collagen and gelatin are used synonymously unless otherwise specified) or take them as a biological component or extract soup mainly containing these. However, it is unclear whether an effective dose is being taken to improve treatment.
In addition, conventional cancer treatments, particularly solid cancer treatments, include systemic methods such as chemotherapy and hormone therapy, and local therapies such as surgery and radiation therapy. However, from the view that cancer will not be cured, all have come to aim for gradual treatment such as prolonging life. In fact, cancers that easily metastasize, such as hepatocellular carcinoma, have a strong tendency to infiltrate into the vasculature, and in particular, have a strong tendency to infiltrate the portal vein, and are difficult to treat. In this case, local treatment (liver artery embolization, percutaneous ethanol injection therapy, microwave coagulation therapy, radiofrequency ablation therapy) is difficult to cope with. Chemotherapy is not an effective treatment method because the effective rate is as low as about 10% even with single administration of any drug and the side effects are strong.
[0003]
[Problems to be solved by the invention]
The object of the present invention is to respond to the above-mentioned idea of “medicine and food consortium” and provide foods and drinks such as health foods and pharmaceuticals using animal-derived active substances, particularly specific collagen, from foods.
Furthermore, the object of the present invention is to develop a new bio-based anticancer agent that suppresses particularly proliferative and metastatic cancers.
In osteoporosis, which is often seen in recent years, administration of bone-derived substances and active substances derived from living bodies is desired. However, for actual treatment and prevention, calcium and bone meal are applied, and otherwise vitamins K and D are applied. However, there is no active ingredient derived from a remarkable living body. In order to overcome this situation, the inventors have intensively researched and found that a specific amount of specific collagen is used to solve the problem.
On the other hand, when cancer cells become active, the basement membrane is destroyed and expands, but there is no effective biological agent. Conventionally, therapeutic agents for cancer diseases have the drawback of having strong side effects when administered for a long time. There has been a demand for a therapeutic agent for cancer diseases that can be safely administered with no side effects in long-term treatment. The present invention is to suppress the metastasis and growth of cancer by using type IV collagen, which is a main component of the basement membrane, and its antibody as an effective substance.
[0004]
[Structure of the invention]
The present invention relates to extracting specific collagen, which is a central component of each part of a living body, and using it as food and drink such as health foods and pharmaceuticals. Furthermore, the present invention relates to an anticancer agent comprising type IV collagen and / or a fraction thereof or a peptide itself and an antibody recognizing these.
The type of collagen used as the anticancer agent may be a mixture of each type or a single type, but type IV collagen is particularly desirable when used alone. The part of the collagen used as the anticancer agent may be the whole collagen, the fraction or peptide constituting the part, or a mixture thereof. Normally, type IV collagen is divided into three regions: NC1 (C-terminal non-helical part), central triple-stranded helical part (with internal disorder), and 7S (N-terminal triple-stranded helical part). These are fractionated from alpha 1 to 6, but may be used alone or in combination when used as an anticancer agent, preferably a triple-stranded helix (central and / or N-terminal, hereinafter triple-stranded) is more desirable. Is a triple stranded alpha 1 and / or alpha 2 peptide. The type IV collagen triple chain has different molecular weights depending on the organ of origin (placenta, kidney glomerulus, ophthalmic lens capsule, various tissue basement membranes), extraction conditions and purification conditions. When it migrates, it belongs to about 50K to about 100K rather than about 180K to about 160K or about 30K.
[0005]
Collagen exists in the living body, has various types, and is a safe component. Since collagen accounts for about 30% of body protein, healthy people always take collagen as a source of animal protein in their daily diet. For example, animals are eaten raw (eg raw eggs, steak rares, horse sashimi, fish sashimi, vinegar of bun cartilage), animals are cooked, dried, extracted (eg, soup containing cartilage) Is taken into the living body. Collagen is widely used as confectionery (commonly known as gummy) and health food, and can be safely taken orally. Collagen is used to safely proliferate cells as a scaffold during animal cell culture. Further, denatured collagen (gelatin) is added as an excipient, a stabilizer and the like to vaccines, internal medicines and injections.
[0006]
As a result of many years of research, the present inventor has found that the strengthening of connective tissue containing normal and tissue-specific collagen suppresses the progression of disease in the tissue. Furthermore, it has been found that administration of normal and tissue-specific collagen is good for strengthening.
[0007]
The collagen may be a tissue that is easily available, for example, type I or III collagen derived from the dermis or type IV collagen derived from placenta, but the same type as the type of collagen contained in the tissue to be treated is preferred and most preferred This is derived from the tissue to be improved or treated or strengthened, but is not limited thereto.
[0008]
Collagen is usually known to contain telopeptides and those from which telopeptides have been removed. In the present invention, both can be used alone or in combination. The removed one is preferred. Furthermore, in the present invention, the collagen may be denatured, modified, reduced in molecular weight, produced by a peptide synthesizer, or a combination thereof. That is, it may be modified to gelatin, which may be modified by succinylation or the like, or may have a low molecular weight.
[0009]
In the present invention, collagen is derived from mammals, birds, fish, crustaceans, reptiles, insects, fungi, etc., such as humans, monkeys, cows, pigs, whales, rats, mice, horses, rabbits, goats, chickens Any organism such as fish, crab, shrimp, frog, frog, insect, Escherichia coli, etc., or a mixture thereof may be used.
[0010]
Collagen can be produced by known methods such as biological extraction, tissue / cell culture, genetic engineering, etc. ("extracellular matrix research method" published by Collagen Technology Workshop), or by using a peptide synthesizer. But it ’s okay.
In order to produce collagen from a living body, generally, there are acid extraction such as hydrochloric acid and acetic acid and enzyme extraction such as pepsin, and both may be combined. Further, it may be purified by DEAE column chromatography or dialysis of the molecular weight cut off, and if it is trace amount, it may be purified by HPLC.
1) An example of producing type IV collagen from the placenta is shown.
Hereinafter, it is performed at 4C as much as possible. Human placenta is shredded and washed (purified water-0.05M Tris buffer pH 7.5 containing purified protease inhibitor-purified water)-freeze-dried and pulverized-0.5ps acetic acid containing pepsin (only acetic acid may be used) Solubilize and collect supernatant by centrifugation (precipitate resolubilized, repeat approximately 5 times)-Add final concentration 0.7M sodium chloride-Collect supernatant by centrifugation-Add final concentration 1.2M sodium chloride-Precipitate by centrifugation Sampling-Dissolving dialysis in 0.05 M Tris buffer pH 7.5 containing 1 M sodium chloride-Adding 4.5 M sodium chloride-Precipitation by centrifugation-Dissolving dialysis in 0.05 M Tris buffer pH 7.5 containing 1.0 M sodium chloride -Supernatant collection by centrifugation-Addition of 4.5 M sodium chloride-Precipitation (type IV collagen)-Purification by column chromatography.
There is also an example manufactured in the published patent publication (Showa 62-53927).
2) An example of producing type I and III collagen from the placenta is shown.
Hereinafter, it is performed at 4C as much as possible. Human placenta is shredded-washed (protease inhibitor-containing PBS) and centrifuged (this operation is repeated about 6 times)-freeze-dried and ground-pepsin-containing 0.5 M acetic acid (only acetic acid may be used) Solubilize and collect supernatant by centrifugation (precipitate is resolubilized, repeat approximately 5 times)-Add final concentration 2M sodium chloride-Collect precipitate by centrifugation-Dissolve in 0.05M acetic acid-Collect supernatant by centrifugation-Finish Add 1M sodium chloride concentration-Collect the precipitate by centrifugation-Dissolve in 0.05M acetic acid-Dialyze and centrifuge-Supernatant (type I), precipitate (type III)-Further dialyze and purify.
In addition, when making type I and III collagen from the dermis, for example, when using bovine fetus or calf dermis, the skin is sufficiently removed and the fat is removed. For degreasing, a mixture of diethyl ether and ethanol (1: 1) is used.
[0011]
Furthermore, when used as an anticancer agent, it is possible to use not only the collagen in the present invention but also an antibody against it. When an antibody is used, monoclonal is preferable to polyclonal, and more preferably a human monoclonal antibody.
When mouse or rat monoclonal antibodies are administered to humans, neutralizing antibodies are produced over a long period of time, and the effect is weakened. Immunoglobulin as an antibody may be IgG1, IgM such as IgG1 or G2a, and other types, or may be a mixture of each type, and further reduced, for example, H chain, L chain, Fc, Fab, F (ab ′) 2. Others are good as long as they have reactivity with the antigen.
[0012]
The foods and drinks such as health foods used as the present invention include not only so-called health foods but also arbitrary food forms such as foods for specified health use, quasi drugs, and general foods and drinks.
[0013]
The daily dose of the collagen of the present invention is usually 0.1 g or more for foods and drinks such as health foods, and a preferred range is 1 to 100 g, and a particularly preferred range is 5 to 10 g.
The collagen of the present invention as an osteoporosis drug is 1 to 30 g per day, preferably 5 to 15 g per day.
The amount of the collagen of the present invention as an anticancer agent is 0.001 mg to 30 g per day, preferably 0.01 mg to 10 g per day, and the amount of antibody is 0.001 mg to 30 g per day, preferably 0 per day. 0.01 mg to 10 g. The numerical value is a guideline and should be increased or decreased depending on the severity of the disease and the condition of the user, and is not limited to this.
[0014]
The administration method of the present invention is not particularly limited as long as it is a method that is usually used as a medical site or food, such as oral administration, injection, and in vivo placement. Administration time may be any after meals, between meals, before going to bed, or a combination thereof, and the number of administrations per day is not particularly limited.
For example, when type IV collagen is used as an anticancer agent to locally treat metastatic liver cancer. By injecting 0.01 mg to 1 g of type IV collagen alone or microparticles containing this into a liver artery from a catheter and forming an embolus while confirming by angiography, metastasis and proliferation of the anticancer agent are suppressed.
[0015]
The intake (administration) form of the present invention may be in the form of existing health foods and pharmaceuticals such as powders, tablets, liquids and capsules. As excipients in the form of internal use, those which are usually used and required for the form of internal use can be applied. For example, starch, lactose, etc. are used as a bulking agent. A flavoring agent, a sweetening agent, a coloring agent, an excipient and the like may be added as necessary.
[0016]
Further, it may be an injection, an internal preparation, an external preparation, or a local administration form like existing pharmaceuticals.
The main agent may be collagen alone or antibody alone, or may be mixed with other drugs to be used as an internal medicine or injection. Other drugs are not particularly limited, drugs that can be usually used as pharmaceuticals, such as digestive agents, intestinal regulating agents, anti-ulcer agents, antibiotics, hormones, enzymes, steroids, endocrine agents, cardiovascular agents, anti-rheumatic agents, Examples include anti-inflammatory agents, analgesics, antipyretic agents, antiallergic agents, antitumor agents, and peptides such as interferons, interleukins, and tumor necrosis factors.
[0017]
When used as a solution in foods and drinks such as the health food of the present invention, pharmaceuticals such as internal medicine, injections, etc., the solution is sterilized purified water, a water-soluble solvent (for example, glycerin), an oily solvent (for example, purified olive oil), etc. Can be used alone or in combination. In addition, in pharmaceutical products such as health foods and other foods and oral medicines and injections of the present invention, as additives, isotonic agents, buffers, solubilizers, surfactants, stabilizers, preservatives, Oils and fats, water-soluble polymers, local anesthetics and the like may be added. The isotonic agent is an inorganic salt such as sodium chloride, the buffer is an inorganic acid such as phosphoric acid, and the citric acid is an organic acid, the surfactant is gelatin, polysorbate 80, the fats and oils are vegetable oils, etc. Examples of the water-soluble polymer include sodium carboxymethyl cellulose.
Furthermore, in the foods and beverages such as health foods, the oral solution, and the injection of the present invention, the additives other than the isotonic agent and the buffer are dissolved or suspended in the solution or suspension thus prepared. It may be clouded.
The solution or suspension thus prepared is sterilized using a Millipore filter, etc., and then filled into a bottle, vial or ampoule to produce the health food liquid, oral liquid, or injection of the present invention. Can do. In the liquid of the present invention, the bottle, vial or ampoule produced can be freeze-dried to obtain a solution for use.
[0018]
【The invention's effect】
From the idea of the same source of medical foods, the necessary active ingredients are obtained from daily foods and drinks, especially from animal ingredients, and are made into health foods or pharmaceutical forms that can be efficiently ingested in vivo to prevent disease and It is provided for treatment. The same applies to the antibody. Collagen in particular is a safe food and drink such as health foods and drugs that do not show any side effects of self-intention even when used for a long period of 2 months or longer.
Hereinafter, the present invention will be further described with reference to examples, but the present invention is not limited thereto.
[0019]
Example 1-1
Type IV collagen NC1 (bovine origin, here using kidney origin), type IV collagen (human origin, here placenta origin, using pepsin treatment, the following three chains) and antibodies (rabbit), which are the main components of the basement membrane Origin, here anti-NC1 antiserum) was examined for anticancer action.
NC1, triple chain and its antiserum were added to a culture of cancer cells (HEPG2) for comparison.
As a result, the triple chain most inhibited the growth of cancer cells. Antiserum (derived from rabbit) also had a suppressive effect. NC1 (derived from bovine) was also suppressed by increasing the concentration.
Figure 0004487277
* Average number of cells in each of 6 wells * Culture conditions BMEM + 10% FBS, 5% CO 2 concentration, 37C
[0020]
Example 1-2
Using the cell “B16 mouse melanoma (melanoma)”, a culture experiment was conducted according to “Example 1-1”. Type I collagen (derived from human placenta, the same in the following experiments).
Figure 0004487277
[0021]
Example 1-3
Using the cell “FBJLL mouse Osteocarcunoma”, a culture experiment was conducted according to “Example 1-1”.
Figure 0004487277
[0022]
Example 1-4
Using the cell “OVCAR4 human Ovarian cancer cell”, a culture experiment was conducted according to “Example 1-1”.
Figure 0004487277
[0023]
Example 1-5
Using the cell “HT1080 human Fibrosarcoma”, a culture experiment was conducted according to “Example 1-1”.
Figure 0004487277
[0024]
Example 1-6
Using a cell “human Human gastric carinoma”, a culture experiment was conducted according to “Example 1-1”.
Figure 0004487277
[0025]
[Example 2]
The effect of safety collagen on healthy subjects was confirmed. Two healthy volunteers warmed a commercial sports drink (Otsuka Pharmaceutical) solution containing about 10% of pork bone-derived collagen (collagen technical workshop of type I collagen 80% or more), about 100 ml (collagen after eating twice a day) The content of about 10 g) was taken for 1 month, but during use, there was no noticeable change in consciousness either immediately after use or after 1 month of taking the drug.
[0026]
[Example 3]
Effectiveness Three porcine osteoporosis patients who walk for more than 1 hour every day take the consent of pork bone collagen (type I collagen 80% or more, collagen technology workshop) in commercial sports drink (Otsuka Pharmaceutical) solution with sufficient consent. I took it. The amount of internal use corresponds to 5 g of collagen after eating three times a day.
As a result, one person had a 3% increase in bone density since the shortest month, and an increase of 8% after 2 months. The other two did not change.
[0027]
[Example 4]
About 10 g of porcine dermis-derived collagen (type I and type III collagen collagen technical workshop) once a day before going to bed with the prior consent of an osteoporotic patient (70 years old, female) who has experienced an effective fracture. Was suspended in 40 ml of orange juice (containing about 10 mg of vitamin C) and taken for 40 days. As a result, the bone density increased by 5% (measurement error by DEXA method is within 2%).

Claims (1)

ヒト胎盤由来タイプIVコラーゲン三本鎖螺旋領域ペプチドを含む肝ガンおよび骨ガンより選ばれる癌に対する抗ガン剤Anticancer agent against cancer selected from liver cancer and bone cancer containing human placenta-derived type IV collagen triple chain region peptide
JP2001298490A 2000-08-30 2001-08-23 Foods and beverages and pharmaceuticals such as health foods Expired - Lifetime JP4487277B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001298490A JP4487277B2 (en) 2000-08-30 2001-08-23 Foods and beverages and pharmaceuticals such as health foods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000305518 2000-08-30
JP2000-305518 2000-10-03
JP2001298490A JP4487277B2 (en) 2000-08-30 2001-08-23 Foods and beverages and pharmaceuticals such as health foods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009021973A Division JP2009148275A (en) 2000-08-30 2009-01-07 Food for specified health use
JP2009293314A Division JP5190637B2 (en) 2000-08-30 2009-12-06 Foods and beverages and pharmaceuticals such as health foods

Publications (2)

Publication Number Publication Date
JP2002173446A JP2002173446A (en) 2002-06-21
JP4487277B2 true JP4487277B2 (en) 2010-06-23

Family

ID=26601568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001298490A Expired - Lifetime JP4487277B2 (en) 2000-08-30 2001-08-23 Foods and beverages and pharmaceuticals such as health foods

Country Status (1)

Country Link
JP (1) JP4487277B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009148275A (en) * 2000-08-30 2009-07-09 Morisuke Yokoyama Food for specified health use
AU2003262277A1 (en) * 2002-12-03 2004-06-23 Koken Co., Ltd. Inhibitor of proliferation and/or infiltration of tumor cells
US8114607B2 (en) 2006-06-12 2012-02-14 Tsukao Yokoyama Type IV collagen-like immunoreactive peptide
CN104814375B (en) * 2015-05-22 2018-05-15 浙江海力生生物科技股份有限公司 A kind of tumor patient full nutrition formula food and preparation method thereof

Also Published As

Publication number Publication date
JP2002173446A (en) 2002-06-21

Similar Documents

Publication Publication Date Title
KR100996985B1 (en) Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level
CN102099050A (en) Orally administrable dosage forms comprising angiogenin and uses thereof
CN102462837B (en) Anti-inflammatory composition
JP2009197030A (en) Mucosal immunomodulator and its use
JP6218732B2 (en) Composition for preventing or treating osteoarthritis
JP2023513435A (en) Animal-free dietary collagen
JP2001510447A (en) Lectin composition and use thereof
CN101152568A (en) Polypeptide combination preparations having functions of accelerating angiogenesis, organ reactivation and wound healing
JP5190637B2 (en) Foods and beverages and pharmaceuticals such as health foods
JP7032855B2 (en) Compositions for altering the expression of clock genes
JP4487277B2 (en) Foods and beverages and pharmaceuticals such as health foods
CN106492216A (en) Nano antibody drug-delivery preparation system and preparation method and application through exocuticle in incidence
EP0834321B1 (en) Oral remedy for rheumatoid arthritis and functional food
JP2014530223A (en) Egg preparation with regenerative, analgesic and / or anti-inflammatory properties
JPH0640938A (en) Hgf-containing pharmaceutical preparation
AU2016272477B2 (en) Enzyme-treated milk product, method for producing same, composition, and product
JP3634721B2 (en) Preventive or therapeutic agent for hyperlipidemia
US20160375061A1 (en) Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases
CN106573034B (en) Marine peptides and fish nucleotides, compositions and uses thereof for lowering blood glucose
JP2017039652A (en) Edible composition for prevention or improvement of metabolic syndrome
Jacobs et al. Alterations in serum levels, anti-tumor activity and toxicity of methotrexate in rats after a short period of nutritional depletion
JP3652865B2 (en) Mixture of lactic acid condensate and composition containing the same
Lennard-Jones et al. Historical Overview of Intestinal Failure
WO2022020421A1 (en) Cannabinoid compositions and methods for treating joint pain and inflammation
Jannin et al. Pronostic variable des non-islet-cell tumor hypoglycemia (NICTH)

Legal Events

Date Code Title Description
A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080715

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080909

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20081029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090324

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090908

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100319

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130409

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4487277

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term